Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Interesting Situation ...
View:
Post by drippingsnot on Sep 06, 2020 11:41pm

Interesting Situation ...

Knight wants to grow Mexico.

Knight has also been funding Moksha8 in Mexico/Brazil since February 2019.
Moksha8 has been making progress with licensing deals since that time.
     - 1 deal in Mexico
     - 5 deals in Mexico/Brazil.
At yearend, Moksha8 had $12 million USD in outstanding loans with GUD at an interest rate of 15-17% ... that's some high risk lending I'd say.
Knight owns warrants equal to 5% of the fully diluted shares of Moksha8.

Knight has earmarked $100M USD at Knight's sole discretion for corporate development at Moksha8.

What happens here?  Does Moksha8 become a competitor, a partner or an acquisition for GUD?
Comment by Snowballgrowth on Sep 07, 2020 6:44am
Good question !
Comment by kentucky77 on Sep 07, 2020 11:00am
Sounds like a good growth strategy... looks like a potential acquisition given the low rate of sales they have in Mexico.  17% interest is the writing on the wall. 
Comment by drippingsnot on Sep 07, 2020 2:07pm
That's what I'm thinking Kentucky ... at a 17% interest rate, Moksha8 is desperate. Keep in mind too - the owners of Moksha8 is an equity firm and they should have access to cash.  Doesn't seem to be the case, or they know the cash alone won't do it ... the business needs GUD's help. Moksha8 CEO Joel Barlan said: “We are thrilled with this partnership. Moksha8 is ...more  
Comment by Snowballgrowth on Sep 07, 2020 7:40pm
Did you see Knight's observers on the board ? I didn't https://www.moksha8.com/board-of-directors.html https://www.globenewswire.com/news-release/2019/02/18/1733742/0/en/Knight-Signs-GUD-Bueno-Latin-American-Strategic-Funding-Deal-with-Moksha8.html
Comment by drippingsnot on Sep 07, 2020 8:42pm
I'm not too sure what the term "observer" really means so I assumed it wasn't an official title - otherwise you'd think they would have been called them board members. Also it says we have "the right to" observers but we don't know the details of the agreement - could we get observers after a certain dollar amount is borrowed ? Googled a definition ... A ...more  
Comment by Snowballgrowth on Sep 07, 2020 9:42pm
  For more the priorities should be optimisation, BD and buyback. I would be very surprised if J. Goodman / Knight don't buy below book value. That said they now need  more products to add value in the sales team hands. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities